Organization and Significant Accounting Policies - Geographical Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 244,293	$ 148,211	[1]
North America
Disaggregation of Revenue [Line Items]
Revenue	86,937	78,296
Europe, the Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue	136,047	53,715
Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	21,195	15,980
Latin and Central America
Disaggregation of Revenue [Line Items]
Revenue	114	220
Nucleic Acid Production
Disaggregation of Revenue [Line Items]
Revenue	223,650	123,932
Nucleic Acid Production | North America
Disaggregation of Revenue [Line Items]
Revenue	79,418	68,132
Nucleic Acid Production | Europe, the Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue	131,350	47,898
Nucleic Acid Production | Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	12,867	7,885
Nucleic Acid Production | Latin and Central America
Disaggregation of Revenue [Line Items]
Revenue	15	17
Biologics Safety Testing
Disaggregation of Revenue [Line Items]
Revenue	20,643	17,649
Biologics Safety Testing | North America
Disaggregation of Revenue [Line Items]
Revenue	7,519	6,412
Biologics Safety Testing | Europe, the Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue	4,697	4,349
Biologics Safety Testing | Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	8,328	6,735
Biologics Safety Testing | Latin and Central America
Disaggregation of Revenue [Line Items]
Revenue	$ 99	153
Protein Detection
Disaggregation of Revenue [Line Items]
Revenue		6,630
Protein Detection | North America
Disaggregation of Revenue [Line Items]
Revenue		3,752
Protein Detection | Europe, the Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue		1,468
Protein Detection | Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue		1,360
Protein Detection | Latin and Central America
Disaggregation of Revenue [Line Items]
Revenue		$ 50

[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification 842 (“ASC 842”). See Note 1 to the condensed consolidated financial statements for a summary of the adjustments.